AI tool predicts Parkinson's progression and medication side effects using a smartwatch
Tests AI models using smartwatch data and health records in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
Key facts
- Where
- Madrid, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 80 with Parkinson's disease for 5 to 10 years, in stages 2 and 3, who use a compatible smartphone.
- Age
- 40 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease diagnosed by MDS criteria, disease duration 5 to 10 years, Hoehn and Yahr stages 2 and 3 in the ON condition.
- Earlier treatment
- People on second-line device-aided treatments cannot join. People taking more than 4 daily doses of L-DOPA, or a daily levodopa equivalent dose above 1500 mg, cannot join.
Main reasons for not taking part
- Atypical Parkinsonian syndrome
- Second-line device-aided treatments
- More than 4 daily doses of L-DOPA, or daily levodopa equivalent dose above 1500 mg
- Ongoing hallucinations needing short-term treatment adjustment
- Pregnant or breast-feeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07189468, who can take part
Where in Spain
- Hospital Ruber InternacionalMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07189468
- Record updated
- 24 September 2025
- Original description
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.Read full original descriptionShow less
AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.
Inclusion: Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015); Disease duration ranging from 5 to 10 years; Age 40-80; Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition; The participant is using a compatible smartphone; Written informed consent.
Exclusion: Atypical Parkinsonian Syndrome; Second-line device-aided treatments; Patients with >4 daily doses of L-DOPA; Daily levodopa equivalent dose > 1500 mg; Ongoing hallucinations requiring short-term treatment adjustment; Inability to provide informed consent or participate in the study; Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator; Lacking motivation to participate in study procedures - as judged by investigator; Under adult autonomy protection system, legal guardianship or incapacitation; Pregnant and breast-feeding women.